Setrusumab
Sponsors
Ultragenyx Pharmaceutical Inc., Ultragenyx Pharmaceutical Inc
Conditions
Osteogenesis ImperfectaOsteogenesis Imperfecta Type IIIOsteogenesis Imperfecta Type IVOsteogenesis Imperfecta, Type IOsteogenesis imperfecta (OI)osteogenesis imperfecta
Phase 2
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
CompletedNCT03118570
Start: 2017-09-11End: 2020-11-12Updated: 2023-07-05
Setrusumab vs Placebo for Osteogenesis Imperfecta
Active, not recruitingNCT05125809
Start: 2022-02-21End: 2027-04-01Updated: 2026-02-25
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
TerminatedNCT05312697
Start: 2022-04-28End: 2022-07-07Updated: 2025-07-23
An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta
Active, not recruitingCTIS2024-510919-29-00
Start: 2023-05-08Target: 53Updated: 2025-09-30
Phase 3
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta
Active, not recruitingNCT05768854
Start: 2023-06-14End: 2027-04-01Updated: 2026-02-25
An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV
Active, not recruitingCTIS2023-504196-24-00
Start: 2023-10-17Target: 27Updated: 2025-11-13
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
Active, not recruitingNCT06636071
Start: 2024-10-25End: 2028-01-01Updated: 2026-03-13